Fig. 4 | npj Breast Cancer

Fig. 4

From: Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer

Fig. 4

Survival according to trastuzumab treatment and human epidermal growth factor receptor 2 (HER2) status. Kaplan–Meier graphical analysis of DFS and OS according to trastuzumab treatment status (a, b), HER2 status (c, d) and HER2 status excluding trastuzumab treated patients (e, f). IG4,2+ 2018 American Society of Clinical Oncology/College of American Pathologists in situ hybridization group 4 and IHC 2+, NEG negative

Back to article page